Bionure has successfully concluded its Phase 1 clinical study with its lead compound, BN201. The study was aimed at investigating safety, tolerability and pharmacokinetics of single and multiple doses of BN201.Bionure’s initial focus areas are Acute Optic Neuritis (AON) and Multiple sclerosis (MS), for which there still are high unmet medical needs. The mechanism of action of BN201 will enable it to ideally address further indications relevant for a neuroprotective agent, including other neurode...